Similar articles

• Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.

  Suit H, Kooy H, Trofimov A, Farr J, Munzenrider J, DeLaney T, Loeffler J, Clasie B, Safai S, Paganetti H. Suit H, et al. Radiother Oncol. 2008 Feb;86(2):148-53. doi: 10.1016/j.radonc.2007.12.024. Epub 2008 Jan 30. Radiother Oncol. 2008. PMID: 18237800
• [Radiobiological bases of proton therapy].

  Courdi A. Courdi A. Pathol Biol (Paris). 1993 Jan;41(1):117. Pathol Biol (Paris). 1993. PMID: 8391135 French. No abstract available.
• Particle radiation therapy using proton and heavier ion beams.

  Schulz-Ertner D, Tsujii H. Schulz-Ertner D, et al. J Clin Oncol. 2007 Mar 10;25(8):953-64. doi: 10.1200/JCO.2006.09.7816. J Clin Oncol. 2007. PMID: 17350944 Review.
• A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors.

  Palm A, Johansson KA. Palm A, et al. Acta Oncol. 2007;46(4):462-73. doi: 10.1080/02841860701218626. Acta Oncol. 2007. PMID: 17497313 Review.
• [Proton beam therapy].

  Akanuma A. Akanuma A. Rinsho Hoshasen. 1974 Feb;19(2):165-6. Rinsho Hoshasen. 1974. PMID: 4856753 Japanese. No abstract available.